QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=25EF47FF8C260D57B0074C1592C5B2AE;jsessionid=291F53E5A2D8F96C89F630F80B9717EA;jsessionid=11AC0C346C7881ABE352A8F1506D6D08;jsessionid=CC969FDA1A9A3743AC3B3EB0CC1D8453;jsessionid=C2CC5E53997C3CC5E7C473D29201F603 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=25EF47FF8C260D57B0074C1592C5B2AE;jsessionid=291F53E5A2D8F96C89F630F80B9717EA;jsessionid=11AC0C346C7881ABE352A8F1506D6D08;jsessionid=CC969FDA1A9A3743AC3B3EB0CC1D8453;jsessionid=C2CC5E53997C3CC5E7C473D29201F603